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Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer
worldwide. Despite advances in diagnostic and therapeutic methods, survival of HNSCC
remains unchanged over the last 30 years with treatment failure and metastases being
the strongest indicators of poor outcome. Cancer stem cells (CSC) have been identi-
ﬁed in multiple other solid tumors, including breast, prostate, and pancreatic carcinoma.
Recently, a subpopulation of tumor cells has been identiﬁed in HNSCC based on the
overexpression of the cellular marker CD44 and increased activity of aldehyde dehydro-
genase. These cells have been designated CSC based on their stem cell-like properties:
self-renewal, tumorigenesis, and the ability to recapitulate a heterogeneous tumor. Recent
work looking at the role of HNSCCCSC in tumorigenesis has shown that CSC have a greater
capacity for tumor growth, increased motility, and invasive characteristics; in vivo experi-
ments conﬁrm greater metastatic potential in CSC compared to non-CSC. Clinically, CSC
enrichment has been shown to be enhanced in recurrent disease, treatment failure, and
metastasis. CSC represent a novel target of study given their slow growth and innatemech-
anisms conferring treatment resistance. Further understanding of their unique phenotype
may reveal potential molecular targets to improve therapeutic and survival outcomes in
patients with HNSCC.
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INTRODUCTION
Worldwide, head and neck squamous cell carcinoma (HNSCC)
is the sixth most common cancer, affecting over 400,000 patients,
and leading to over 200,000 deaths annually. Over the last 30 years,
there has been limited improvement in survival despite advance-
ment in surgery, radiotherapy, and chemotherapy (Jemal et al.,
2011; Siegel et al., 2011). Metastases and treatment failures account
for the majority of deaths in HNSCC. Improved understanding of
the mechanisms of HNSCC tumorigenesis, metastases and treat-
ment failure may have a signiﬁcant impact on the morbidity and
mortality of HNSCC. It is imperative that we strive for a better
understanding of HNSCC at the cellular and molecular level so
that we might develop more efﬁcient therapies that target the key
pathways of disease initiation and progression.
Tumors were initially thought to arise from multiple different
mutations within cells. As the number of mutations accumulates,
cells ultimately become immortalized, where each cell is capa-
ble of initiating tumor growth (Figure 1A). The cancer stem
cell (CSC) theory of tumorigenesis was originally proposed in
the late 1970s, and has recently gained renewed interest due to
identiﬁcation of CSC in solid organ malignancies (Hamburger
and Salmon, 1977; Vermeulen et al., 2008). The CSC theory
is based on our understanding of embryological development
and stem cell-derived organogenesis, where a few speciﬁc cells
are capable of asymmetric division leading to the generation of
diverse progenitor cells responsible for the creation of complex
and heterogeneous organs. Similarly, the CSC theory explains
that there exists a hierarchy of cells, where CSC are capable of
unregulated asymmetric division, which is responsible for self-
renewal and generation of a diverse population of differentiated
progenitor cells that ultimately make up a heterogeneous tumor.
According to the CSC theory, this subgroup of cells is responsible
for the initiation of tumor growth and spread, whereas non-CSC
are incapable of regenerating progeny or recapitulating a tumor
(Reya et al., 2001; Figure 1B).
Subpopulations of highly tumorigenic cells, or CSC, were ﬁrst
described in hematologic malignancies in 1994 (Lapidot et al.,
1994). Since then they have been identiﬁed in multiple solid
organmalignancies using a variety of cellularmarkers. Al-Hajj and
Clarke were the ﬁrst to demonstrate CSC in breast cancer using the
cellular markers CD44+/CD24−/low/Lineage− cells. These cells
are capable of serial regeneration, recapitulation of the primary
tumor, and self-renewal of the tumor initiating cells (Al-Hajj et al.,
2003; Wicha et al., 2006; Shah et al., 2007). Since then, CSC have
been identiﬁed in multiple other solid organ malignancies, includ-
ing CNS, pancreatic, lung, colon, and recently HNSCC (Singh
et al., 2003; Kim et al., 2005; Li et al., 2007; O’Brien et al., 2007;
Prince et al., 2007).
Work by Prince and colleagues in 2007 was the ﬁrst to iden-
tify a subpopulation of HNSCC tumor cells with stem cell-like
phenotypes, initially using the cellular marker CD44 (Prince et al.,
2007). Like otherCSC, these cells possess the stemcell-like qualities
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FIGURE 1 | (A) In the stochastic model of tumorigenesis all cells are
capable of renewal and tumorigenesis. (B) In the cancer stem cell (CSC)
model, only a select group of cells are capable of asymmetric division and
tumorigenesis.
of self-renewal, tumorigenesis, and the ability to recapitulate a
heterogeneous tumor. This marked the ﬁrst identiﬁcation of CSC
in HNSCC. The purposes of this review are (i) to discuss the meth-
ods of CSC identiﬁcation in HNSCC, (ii) to evaluate the HNSCC
CSC as a mediator of tumorigenesis, metastasis, and treatment
failures, and (iii) to evaluate the evidence for CSC as a potential
target of therapy.
CSC MARKERS
Cancer stemcells are often identiﬁed by speciﬁcmolecularmarkers
or enzymatic reactions. These CSC-speciﬁc markers allow for the
use of ﬂow cytometry to identify and sort a select subpopulation
of cancer cells. The cellular makers CD44, CD133, and aldehyde
dehydrogenase (ALDH) are used to identify head and neck CSC
by ﬂuorescence activated ﬂow cytometry.
CD44 AND CD133
CD44 is a cell surface glycoprotein that mediates cell–cell interac-
tions by binding to hyaluronic acid and other extracellular ligands.
Post-transcriptional andpost-translationalmodiﬁcations toCD44
result in a diverse functional repertoire that includes aiding the
adherence of leukocytes to endothelial cells and the invasion and
subsequent metastasis of cancer cells (Wang et al., 2009). CSC can
be isolated from HNSCC by ﬂuorescence activated cell sorting
(FACS) ﬂow cytometry to identify cells stained with ﬂuorescence-
conjugated CD44 antibodies. CD44high cells are characterized as
having a more primitive, poorly differentiated morphology, and
increased expression of known stem cell markers, such as BMI-1
(Prince et al., 2007, Song et al., 2006).
Similar to CD44, CD133 is a transmembrane glycoprotein
characterized by its tendency to localize to cellular protrusions.
CD133 is a protein commonly expressed in hematopoietic stem
cells, endothelial progenitor cells, and various normal tissue stem
cells. CD133 was ﬁrst described as a CSC marker in leukemia and
glioblastoma. Recently, it has also been described as a CSC marker
in laryngeal squamous cell carcinoma as evidenced by cells with
high CD133 expression exhibiting a CSC phenotype (Bonnet and
Dick, 1997; Zhou et al., 2007). Like CD44, CD133-expressing cells
can be identiﬁed using FACS.
ALDEHYDE DEHYDROGENASE
Aldehyde dehydrogenase is a ubiquitous intracellular enzyme,
catalyzing the oxidation of aldehydes in both physiologic and
pathologic cellular processes. Two speciﬁc isoforms from the
ALDH superfamily of proteins, ALDH1A1 and ALDH3A1, have
been characterized for their pivotal role in both embryonic and
adult stem cell physiology. ALDH was initially identiﬁed as a
marker for embryonic and physiologic stem cells. More recently,
ALDH has been shown to be a marker for CSC in hematologic and
solid organ malignancies (Hess et al., 2004; Matsui et al., 2004;
Brabletz et al., 2005; Pearce et al., 2005; Ginestier et al., 2007;
Clay et al., 2010). Recently, expression of the ALDH1 isoform
has been recognized as a marker for HNSCC and colon can-
cers. Unlike CD44 and CD133, the identiﬁcation of tumor cells
that express high levels of ALDH requires the use of the non-
immunologic enzymatic ALDEFLUORTM Kit and FACS (Chen
et al., 2009; Huang et al., 2009; Clay et al., 2010).
SIDE POPULATIONS
The side population (SP) assay is another method of identifying
stem cell-like populations. Goodell and colleagues isolated a SP of
cells from bone marrow based on their ability to efﬂux the ﬂuores-
cent DNA binding dye Hoechst 33342 compared to non-SP cells.
SP cells are thought to be a source of CSC in hematologic and
solid organ malignancies (Goodell et al., 1997; Hirschmann-Jax
et al., 2004; Kondo et al., 2004; Ho et al., 2007; Wang et al., 2007;
Burkert et al., 2008). Zhang et al. (2009) isolated SP cells from oral
cavity tumors and found they had similar gene expression pro-
ﬁles to other CSC populations including overexpression of BMI-1
and OCT-4.
TUMORIGENESIS
Cancer is deﬁned by unregulated cell division and growth. CSC
are believed to represent a mechanism for tumorigenesis and
potentially offer a novel area of study for developing more effec-
tive treatments for HNSCC. HNSCC CSC were ﬁrst described by
Prince and colleagues in 2007 based on CD44 expression. In their
experiments, they demonstrated enhanced tumorigenicity in the
Frontiers in Endocrinology | Cancer Endocrinology August 2012 | Volume 3 | Article 90 | 2
“fendo-03-00090” — 2012/8/1 — 17:39 — page 3 — #3
Chinn et al. HNSCC cancer stem cells
CD44high subpopulation (as few as 5,000 cells) as compared to
CD44low cells, even when injecting >1 × 106 cells (Prince et al.,
2007). The resulting tumors, derived from theCD44high injections,
demonstrated renewal of CD44high cells, indicating self-renewal,
and regeneration of a heterogeneous tumor, thus meeting the def-
inition of a CSC. Similar experiments using the enzymatic marker
ALDH were also able to demonstrate that cells with ALDH+
expression had greater rates of tumorigenesis in mouse ﬂank
and neck injections (Chen et al., 2009; Clay et al., 2010). This
work has been subsequently repeated by several other studies
(Davis et al., 2010; Campos et al., 2012).
Gene expression signatures in ALDH/CD44-sorted HNSCC
cells demonstrated BMI-1, a known CSC marker, to be dif-
ferentially overexpressed, and when knocked down, demon-
strated reduced tumorigenesis (Krishnamurthy et al., 2010).
Based on these studies, cells expressing CD44high, ALDH+,
and CD44high/ALDH+ demonstrate highly tumorigenic potential
compared to their negative counterparts, while maintaining the
CSC phenotype in perpetuity. However, CD44 and ALDH are not
the only biomarkers capable of distinguishing cells capable of self-
renewal. Sun and Wang (2011) looked at CMET+ cells compared
to CMET− and found increased tumorigenicity in a ﬂank injec-
tions and found higher percentage of implantation in CMET+
cells compared to CD44+ cells and slightly lower than ALDH+
cells. In addition, Zhang et al. (2009) looked at HNSCC cell lines
and oral cavity primary tumors identiﬁed the presence of SP cells.
In vitro and in vivo analysis demonstrated SP cells had greater
clonal expansion and greater tumorigenicity relative to non-SP
cells. Although CD44 and ALDH are the most studied CSC mark-
ers, recent evidence supports the possibility that CSC, much like
all tumor cells are heterogeneous in their genetic and expression
signatures resulting in different phenotypes and varied capacities
for tumorigenesis.
METASTASIS
Regional and distant metastases in HNSCC correspond to
an extremely poor prognosis with limited treatment options.
Improved understanding of the mechanisms and etiology of
metastases may allow for improvement in outcomes for patients
with HNSCC. CSC have been linked with distant metastasis in
breast cancer and pancreatic carcinoma. Analysis of bone marrow
metastases has shown enrichment of cells expressing the breast
CSC marker phenotype (CD44+/CD24−; Balic et al., 2006). In
pancreatic adenocarcinomaa subgroupof pancreaticCSCexpress-
ingCD133+/CXCR4+ were shown to have an enhancedmetastatic
phenotype (Hermann et al., 2007).
In HNSCC, understanding the cellular mechanisms of inva-
sion and metastasis is critical to developing new diagnostics and
therapeutic modalities. CSC offer a unique mechanism for metas-
tasis given their ability for tumor growth at the primary site, but
also at the distant sites. In vitro and in vivo work has shown
that HNSCC CD44high cells have greater migration, invasion and
metastatic potential compared toCD44low cells (Davis et al., 2010).
Gene expression studies comparing ALDH+ cells and ALDH−
cells demonstrated elevated levels of the metastatic and epithelial–
mesenchymal transition (EMT) biomarkers CMET, TWIST, and
SNAIL (Chen et al., 2011; Sun and Wang, 2011).
Side population cells have also been associated with metasta-
sis. In two separate studies, SP cells were found to have higher
incidence of metastasis in an intracardiac injection mouse model
relative to non-SP and were highly enriched in metastatic lesions
(Zhang et al., 2009; Song et al., 2010). These are important ﬁnd-
ings further isolating the genetic and expressome signatures in
cells thought to initiate and propagate metastasis.
Collectively, these ﬁndings support CSC as important medi-
ator and potential target in HNSCC metastasis. However despite
these associations, the evidence and mechanisms of CSC mediated
metastasis remains scant. Similar to tumorigenesis, CSC hetero-
geneity may also have an impact in a CSC ability to invade locally
and metastasize distantly. Understanding the exact mechanisms
remains elusive.
TREATMENT FAILURES AND RESISTANCE TO THERAPY
Similar to the development of metastasis, treatment failure and
recurrence portends a poor prognosis in HNSCC. Despite an
increasing amount of research investigating the mechanisms
responsible for treatment failure and resistance in HNSCC, out-
comes remain largely unchanged. CSC have been shown to be
especially resilient to toxic insult in a variety of malignancies, and
may represent critical mediators of chemo- and radio-resistance
within the diverse cellular population of a tumor. CSC pos-
sess unique mechanisms to resist cell death, including modiﬁed
anti-apoptotic machinery, increased pump activity, and decreased
cell division (Clarke et al., 2006). Glioblastoma and colorec-
tal cells displaying CSC markers were enriched in the residual
tumor population following treatment failures with standard
chemotherapeutic agents (Kang and Kang, 2007; Dylla et al.,
2008). When pancreatic carcinoma cells were incubated with
gemcitabine, the proportion of CSC was signiﬁcantly increased
and cells with CSC markers exhibited more aggressive behav-
ior (Shah et al., 2007). In addition to chemo-resistance, the CSC
subpopulation in cervical cancer cells has been shown to resist
radiation damage, and overexpresses genes related to radiation-
resistance, DNA repair, hypoxia, and an invasive phenotype
(Lopez et al., 2012).
In HNSCC, a higher percentage of CD44+ cells in a patient’s
primary tumor has been shown to be associated with higher rates
of treatment failure, while cells expressing the putative CSC mark-
ers CD44, CD24, Oct4, and integrin-b1 were associated with
poor outcomes following radiotherapy (Joshua et al., 2012; Kouk-
ourakis et al., 2012). CSC, as deﬁned by CD44 expression, have a
greater resistance to pro-apoptotic stimuli (TNF-α and anti-Fas
antibody) and a greater capacity for resistance to chemotherapeu-
tic agents compared to non-CSC. At the molecular level, support
forCSC-associated treatment resistance involves overexpression of
anti-apoptotic genes and themultidrug resistantABC transporters
(Okamoto et al., 2009; Chikamatsu et al., 2012). In laryngeal SCC,
cells overexpressing CD133 and ABCG2 demonstrated a signif-
icantly reduced cell death rate when co-cultured with common
HNSCC-speciﬁc chemotherapy agents (Yang et al., 2011). Using
ALDH as a marker of CSC, ALDH+ cells showed similar chemo-
and radiation-resistant patterns, and interestingly, inhibition
of the proposed CSC-mediator, SNAIL, caused reduced ALDH
expression, decreased tumorigenesis and improved chemo- and
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radiation sensitization (Chen et al., 2009). With regard to SP cells,
Zhang et al. (2009) demonstrated they possess qualities necessary
for chemo-resistance, with elevated expression of ABC transporter
proteins.
Invasive and metastatic behavior of epithelial cancers involves
the loss of E-cadherin and transformation to a mesenchymal phe-
notype – a process known as epithelial–mesenchymal transition
(EMT). Once cancer cells transition to a mesenchymal pheno-
type, they become increasingly motile and resistant to therapeutic
options. Interestingly, Mani et al. (2008) established a relation-
ship between these transformed cells and CSC; after induction
of EMT in breast cancer cells, via activation of Snail/Twist, cells
adopted stem-like properties of growth and tumorigenicity. In
addition, just as hypoxia maintains the pluripotency of embryonic
stem cells, a similar process may be involved with promotion of
the CSC phenotype and its anti-apoptotic characteristics; hypoxia
often represents low blood ﬂow, which limits the distribution of
chemotherapeutic drugs, and causes increased resistance to radi-
ation, which requires sufﬁcient oxygen tension to produce oxygen
free radicals for cytotoxicity. Hypoxia inducible factors (HIFs) are
overexpressed in CSC and may be responsible for some aspect of
radiation-resistance in HNSCC (Vlashi et al., 2009). The enhanced
mechanisms of CSC to endure and adapt to toxic insults may
help explain treatment failures and poor outcomes in HNSCC,
and a more sophisticated understanding of their unique survival
machinerymay illuminate points of vulnerability and lead to novel
CSC-speciﬁc targets.
CLINICAL IMPLICATIONS OF HNSCC CSC AND FUTURE AIMS
The use of CSC as markers for novel diagnostic and therapeu-
tic targets is appealing. CD44 levels have been shown to be
elevated in peripheral blood samples of HNSCC patients com-
pared to healthy controls (Faber et al., 2011). Joshua et al. (2012)
found that HNSCC primary tumors with elevated CD44+ cells
(>36%) had an increased risk of recurrence of their primary
tumor compared to tumorswith lower CD44+ levels (<15%). The
use of CSC markers for screening and early diagnosis may have a
positive impact on outcomes. Likewise, understanding the enrich-
ment of CSC in primary tumors may enhance our understanding
of tumor behavior, enhance surveillance, and better predict
outcomes.
Increasing evidence supports CSC as mediators of tumorigen-
esis, metastasis, and treatment failure. Current therapies toward
HNSCC are not CSC-speciﬁc and may result in inadequate CSC
death. Given the evidence that only a small number of CSC are
capable of tumorigenesis, any remaining CSC increase the risk of
recurrence,metastasis, and ultimately poor outcomes (Figure 2A).
CSC-directed treatment in HNSCC tumors is crucial in targeting
the speciﬁc subpopulation of cells that is responsible for treat-
ment failures and poor outcomes (Figure 2B). However,much like
cancer biology in general, CSC biology is a complex heterogeneous
FIGURE 2 | (A) Standard treatment modalities with cancer stem cell (CSC)
mediated treatment failure and metastasis. (B)Targeted CSC therapy
potentially leading to improved outcomes.
process (Vermeulen et al., 2012). Similarly, not all CSC may have
the same potential. Further study of HNSCC CSC heterogene-
ity and identifying CSC subsets may aid in better explaining CSC
pathophysiology.
CONCLUSION
The ﬁndings that head and neck CSC are intrinsic to the malig-
nant physiology of tumors that are profoundly difﬁcult to treat
make them an attractive area of study. Future work to better
understand the CSC-speciﬁc molecular pathways will be critical
in understanding the mechanisms of tumorigenesis, metastasis,
and treatment failures with the ultimate goal of developing novel
CSC diagnostics and therapeutic targets.
REFERENCES
Al-Hajj, M., Wicha, M. S., Benito-
Hernandez, A., Morrison, S. J., and
Clarke, M. F. (2003). Prospective
identiﬁcation of tumorigenic breast
cancer cells. Proc. Natl. Acad. Sci.
U.S.A. 100, 3983–3988.
Balic, M., Lin, H., Young, L., Hawes,
D., Giuliano, A., McNamara, G.,
Datar, R. H., and Cote, R. J. (2006).
Most early disseminated cancer cells
detected in bone marrow of breast
cancer patients have a putative breast
cancer stem cell phenotype. Clin.
Cancer Res. 12, 5615–5621.
Bonnet, D., and Dick, J. E. (1997).
Human acute myeloid leukemia is
organized as a hierarchy that origi-
nates from a primitive hematopoietic
cell. Nat. Med. 3, 730–737.
Frontiers in Endocrinology | Cancer Endocrinology August 2012 | Volume 3 | Article 90 | 4
“fendo-03-00090” — 2012/8/1 — 17:39 — page 5 — #5
Chinn et al. HNSCC cancer stem cells
Brabletz, T., Jung, A., Spaderna,
S., Hlubek, F., and Kirchner, T.
(2005). Opinion: migrating cancer
stem cells – an integrated concept of
malignant tumour progression. Nat.
Rev. Cancer 5, 744–749.
Burkert, J., Otto, W. R., and Wright,
N. A. (2008). Side populations
of gastrointestinal cancers are not
enriched in stem cells. J. Pathol. 214,
564–573.
Campos, M. S., Neiva, K. G., Meyers,
K. A., Krishnamurthy, S., and Nör,
J. E. (2012). Endothelial derived fac-
tors inhibit anoikis of head and neck
cancer stem cells. Oral Oncol. 48,
26–32.
Chen, C., Wei, Y., Hummel, M., Hoff-
mann, T. K., Gross, M., Kaufmann,
A. M., and Albers, A. E. (2011).
Evidence for epithelial–mesenchymal
transition in cancer stem cells of
head and neck squamous cell car-
cinoma. PLoS ONE 6, e16466. doi:
10.1371/journal.pone.0016466
Chen, Y.-C., Chen, Y.-W., Hsu, H.-S.,
Tseng, L.-M., Huang, P.-I., Lu, K.-
H., Chen, D.-T., Tai, L.-K., Yung,
M.-C., Chang, S.-C., Ku, H. H.,
Chiou, S. H., and Lo, W. L. (2009).
Aldehyde dehydrogenase 1 is a puta-
tive marker for cancer stem cells
in head and neck squamous cancer.
Biochem. Biophys. Res. Commun. 385,
307–313.
Chikamatsu, K., Ishii, H., Taka-
hashi, G., Okamoto, A., Moriyama,
M., Sakakura, K., and Masuyama,
K. (2012). Resistance to apoptosis-
inducing stimuli in CD44+ head and
neck squamous cell carcinoma cells.
Head Neck 34, 336–343.
Clarke, M. F., Dick, J. E., Dirks, P. B.,
Eaves, C. J., Jamieson,C.H.M., Jones,
D. L., Visvader, J., Weissman, I. L.,
and Wahl, G. M. (2006). Cancer stem
cells – perspectives on current status
and future directions: AACR work-
shop on cancer stem cells. Cancer Res.
66, 9339–9344.
Clay, M. R., Tabor, M., Owen, J. H.,
Carey, T. E., Bradford, C. R., Wolf,
G. T., Wicha, M. S., and Prince,
M. E. (2010). Single-marker identi-
ﬁcation of head and neck squamous
cell carcinoma cancer stem cells with
aldehyde dehydrogenase. Head Neck
32, 1195–1201.
Davis, S. J., Divi, V., Owen, J.
H., Bradford, C. R., Carey, T. E.,
Papagerakis, S., and Prince, M.
E. P. (2010). Metastatic potential
of cancer stem cells in head and
neck squamous cell carcinoma. Arch.
Otolaryngol. Head Neck Surg. 136,
1260–1266.
Dylla, S. J., Beviglia, L., Park, I.
K., Chartier, C., Raval, J., Ngan,
L., Pickell, K., Aguilar, J., Lazetic,
S., and Smith-Berdan, S. (2008).
Colorectal cancer stem cells are
enriched in xenogeneic tumors fol-
lowing chemotherapy. PLoS ONE
3, e2428. doi: 10.1371/journal.pone.
0002428
Faber, A., Barth, C., Hörmann, K.,
Kassner, S., Schultz, J. D., Sommer,
U., Stern-Straeter, J., Thorn, C., and
Goessler,U.R. (2011). CD44as a stem
cell marker in head and neck squa-
mous cell carcinoma. Oncol. Rep. 26,
321–326.
Ginestier, C., Hur, M. H., Charafe-
Jauffret, E., Monville, F., Dutcher,
J., Brown, M., Jacquemier, J., Viens,
P., Kleer, C. G., Liu, S., Schott, A.,
Hayes, D., Birnbaum, D., Wicha, M.
S., and Dontu, G. (2007). ALDH1 is
a marker of normal and malignant
human mammary stem cells and a
predictor of poor clinical outcome.
Cell Stem Cell 1, 555–567.
Goodell, M. A., Rosenzweig, M., Kim,
H., Marks, D. F., DeMaria, M., Par-
adis, G., Grupp, S. A., Sieff, C. A.,
Mulligan, R. C., and Johnson, R. P.
(1997). Dye efﬂux studies suggest that
hematopoietic stem cells expressing
low or undetectable levels of CD34
antigen exist in multiple species. Nat.
Med. 3, 1337–1345.
Hamburger, A. W., and Salmon, S.
E. (1977). Primary bioassay of
human tumor stem cells. Science 197,
461–463.
Hermann, P. C., Huber, S. L., Herrler, T.,
Aicher, A., Ellwart, J. W., Guba, M.,
Bruns, C. J., and Heeschen, C. (2007).
Distinct populations of cancer stem
cells determine tumor growth and
metastatic activity in human pan-
creatic cancer. Cell Stem Cell 1,
313–323.
Hess, D. A., Meyerrose, T. E.,
Wirthlin, L., Craft, T. P., Her-
rbrich, P. E., Creer, M. H., and
Nolta, J. A. (2004). Functional
characterization of highly puriﬁed
human hematopoietic repopulating
cells isolated according to aldehyde
dehydrogenase activity. Blood 104,
1648–1655.
Hirschmann-Jax, C., Foster, A. E., Wulf,
G. G., Nuchtern, J. G., Jax, T. W.,
Gobel, U., Goodell, M. A., and Bren-
ner, M. K. (2004). A distinct “side
population” of cells with high drug
efﬂux capacity in human tumor cells.
Proc. Natl. Acad. Sci. U.S.A. 101,
14228–14233.
Ho, M. M., Ng, A. V., Lam, S., and
Hung, J. Y. (2007). Side popula-
tion in human lung cancer cell lines
and tumors is enriched with stem-
like cancer cells. Cancer Res. 67,
4827–4833.
Huang, E. H., Hynes, M. J., Zhang, T.,
Ginestier, C., Dontu, G., Appelman,
H., Fields, J. Z., Wicha, M. S., and
Boman,B.M. (2009). Aldehyde dehy-
drogenase 1 is a marker for normal
and malignant human colonic stem
cells (SC) and tracks SC overpop-
ulation during colon tumorigenesis.
Cancer Res. 69, 3382–3389.
Jemal, A., Bray, F., Center, M. M., Ferlay,
J., Ward, E., and Forman, D. (2011).
Global cancer statistics. CA Cancer J.
Clin. 61, 69–90.
Joshua, B., Kaplan, M. J., Doweck, I.,
Pai, R., Weissman, I. L., Prince, M.
E., and Ailles, L. E. (2012). Frequency
of cells expressing CD44, a head and
neck cancer stem cellmarker: correla-
tion with tumor aggressiveness. Head
Neck 34, 42–49.
Kang, M.-K., and Kang, S.-K. (2007).
Tumorigenesis of chemotherapeutic
drug-resistant cancer stem-like cells
in brain glioma. Stem Cells Dev. 16,
837–847.
Kim,C. F. B., Jackson, E. L.,Woolfenden,
A. E., Lawrence, S., Babar, I., Vogel,
S., Crowley, D., Bronson, R. T., and
Jacks, T. (2005). Identiﬁcation of
bronchioalveolar stem cells in nor-
mal lung and lung cancer. Cell 121,
823–835.
Kondo, T., Setoguchi, T., and Taga, T.
(2004). Persistenceof a small subpop-
ulation of cancer stem-like cells in the
C6 glioma cell line. Proc. Natl. Acad.
Sci. U.S.A. 101, 781–786.
Koukourakis, M. I., Giatromanolaki,
A., Tsakmaki, V., Danielidis, V.,
and Sivridis, E. (2012). Cancer
stem cell phenotype relates to radio-
chemotherapy outcome in locally
advanced squamous cell head–neck
cancer. Br. J. Cancer 106, 846–853.
Krishnamurthy, S., Dong, Z., Vodopy-
anov, D., Imai, A., Helman, J. I.,
Prince, M. E., Wicha, M. S., and
Nör, J. E. (2010). Endothelial cell-
initiated signaling promotes the sur-
vival and self-renewal of cancer stem
cells. Cancer Res. 70, 9969–9978.
Lapidot, T., Sirard, C., Vormoor, J.,
Murdoch, B., Hoang, T., Caceres-
Cortes, J., Minden, M., Paterson,
B., Caligiuri, M. A., and Dick, J. E.
(1994). A cell initiating human acute
myeloid leukaemia after transplan-
tation into SCID mice. Nature 367,
645–648.
Li, C., Heidt, D. G., Dalerba, P., Burant,
C. F., Zhang, L., Adsay, V., Wicha,
M., Clarke, M. F., and Simeone, D.
M. (2007). Identiﬁcation of pancre-
atic cancer stem cells. Cancer Res. 67,
1030–1037.
Lopez, J., Poitevin, A., Mendoza-
Martinez, V., Perez-Plasencia, C.,
and Garcia-Carranca, A. (2012).
Cancer-initiating cells derived from
established cervical cell lines exhibit
stem-cell markers and increased
radioresistance. BMC Cancer 12, 48.
doi: 10.1186/1471-2407-12-48
Mani, S. A., Guo, W., Liao, M.-J.,
Eaton, E. N., Ayyanan, A., Zhou,
A. Y., Brooks, M., Reinhard, F.,
Zhang, C. C., Shipitsin, M., Camp-
bell, L. L., Polyak, K., Brisken, C.,
Yang, J., and Weinberg, R. A. (2008).
The epithelial–mesenchymal transi-
tion generates cells with properties of
stem cells. Cell 133, 704–715.
Matsui,W., Huff, C. A.,Wang, Q., Male-
horn, M. T., Barber, J., Tanhehco, Y.,
Smith, B.D., Civin, C. I., and Jones, R.
J. (2004). Characterization of clono-
genic multiple myeloma cells. Blood
103, 2332–2336.
O’Brien, C. A., Pollett, A., Gallinger,
S., and Dick, J. E. (2007). A human
colon cancer cell capable of initiating
tumour growth in immunodeﬁcient
mice. Nature 445, 106–110.
Okamoto, A., Chikamatsu, K.,
Sakakura, K., Hatsushika, K., Taka-
hashi, G., and Masuyama, K. (2009).
Expansion and characterization of
cancer stem-like cells in squamous
cell carcinoma of the head and neck.
Oral Oncol. 45, 633–639.
Pearce, D. J., Taussig, D., Simpson,
C., Allen, K., Rohatiner, A. Z., Lis-
ter, T. A., and Bonnet, D. (2005).
Characterization of cells with a
high aldehyde dehydrogenase activity
from cord blood and acute myeloid
leukemia samples. Stem Cells 23,
752–760.
Prince, M., Sivanandan, R., Kac-
zorowski, A., Wolf, G., Kaplan, M.,
Dalerba, P., Weissman, I., Clarke,
M., and Ailles, L. (2007). Identiﬁ-
cation of a subpopulation of cells
with cancer stem cell properties in
head and neck squamous cell carci-
noma. Proc. Natl. Acad. Sci. U.S.A.
104, 973.
Reya, T., Morrison, S. J., Clarke, M.
F., and Weissman, I. L. (2001). Stem
cells, cancer, and cancer stem cells.
Nature 414, 105–111.
Shah, A. N., Summy, J. M., Zhang, J.,
Park, S. I., Parikh, N. U., and Gallick,
G. E. (2007). Development and char-
acterization of gemcitabine-resistant
pancreatic tumor cells. Ann. Surg.
Oncol. 14, 3629–3637.
Siegel, R., Ward, E., Brawley, O.,
and Jemal, A. (2011). Cancer statis-
tics, 2011: the impact of eliminating
socioeconomic and racial disparities
on premature cancer deaths. CACan-
cer J. Clin. 61, 212–236.
Singh, S. K., Clarke, I. D., Terasaki, M.,
Bonn, V. E., Hawkins, C., Squire, J.,
and Dirks, P. B. (2003). Identiﬁcation
www.frontiersin.org August 2012 | Volume 3 | Article 90 | 5
“fendo-03-00090” — 2012/8/1 — 17:39 — page 6 — #6
Chinn et al. HNSCC cancer stem cells
of a cancer stem cell in human brain
tumors. Cancer Res. 63, 5821.
Song, L. B., Zeng, M. S., Liao, W.
T., Zhang, L., Mo, H. Y., Liu, W.
L., Shao, J. Y., Wu, Q. L., Li, M.
Z., Xia, Y. F., Fu, L. W., Huang,
W. L., Dimri, G. P., Band, V., and
Zeng, Y. X. (2006). Bmi-1 is a novel
molecular marker of nasopharyngeal
carcinoma progression and immor-
talizes primary human nasopharyn-
geal epithelial cells. Cancer Res. 66,
6225–6232.
Song, J., Chang, I., Chen, Z., Kang,
M., and Wang, C. Y. (2010). Char-
acterization of side populations in
HNSCC: highly invasive, chemore-
sistant and abnormal Wnt signal-
ing. PLoS ONE 5, e11456. doi:
10.1371/journal.pone.0011456
Sun, S., and Wang, Z. (2011). Head
neck squamous cell carcinoma c-
Met+ cells display cancer stem cell
properties and are responsible for
cisplatin-resistance and metastasis.
Int. J. Cancer 129, 2337–2348.
Vermeulen, L., de Sousa e Melo, F.,
Richel,D. J., andMedema, J. P. (2012).
The developing cancer-stem-cell mo-
del: clinical challenges and opportu-
nities. Lancet Oncol. 13, e83–e89.
Vermeulen, L., Sprick, M. R., Kem-
per, K., Stassi, G., and Medema, J. P.
(2008). Cancer stem cells – old con-
cepts, new insights. Cell Death Differ.
15, 947–958.
Vlashi, E., McBride, W. H., and Pajonk,
F. (2009). Radiation responses of can-
cer stem cells. J. Cell. Biochem. 108,
339–342.
Wang, J., Guo, L. P., Chen, L. Z., Zeng,
Y. X., and Lu, S. H. (2007). Identi-
ﬁcation of cancer stem cell-like side
population cells in human nasopha-
ryngeal carcinoma cell line. Cancer
Res. 67, 3716–3724.
Wang, S. J., Wong, G., de Heer, A.-
M., Xia, W., and Bourguignon, L. Y.
W. (2009). CD44 variant isoforms in
head and neck squamous cell carci-
noma progression. Laryngoscope 119,
1518–1530.
Wicha, M. S., Liu, S., and Dontu,
G. (2006). Cancer stem cells: an
old idea – a paradigm shift. Can-
cer Res. 66, 1883–1890; discussion
1895–1896.
Yang, J.-P., Liu, Y., Zhong, W., Yu,
D., Wen, L.-J., and Jin, C.-S. (2011).
Chemoresistance of CD133+ cancer
stem cells in laryngeal carcinoma.
Chin. Med. J. 124, 1055–1060.
Zhang, P., Zhang, Y., Mao, L.,
Zhang, Z., and Chen, W. (2009).
Side population in oral squamous
cell carcinoma possesses tumor stem
cell phenotypes. Cancer Lett. 277,
227–234.
Zhou, L. L., Wei, X. X., Cheng, L.
L., Tian, J. J., and Jiang, J. J. J.
(2007). CD133, one of the markers
of cancer stem cells in Hep-2 cell line.
Laryngoscope 117, 455–460.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 30 March 2012; paper pend-
ing published: 25 April 2012; accepted:
02 July 2012; published online: 03 August
2012.
Citation: Chinn SB, Darr OA, Peters RD
and Prince ME (2012) The role of head
and neck squamous cell carcinoma can-
cer stem cells in tumorigenesis, metastasis,
and treatment failure. Front. Endocrin.
3:90. doi: 10.3389/fendo.2012.00090
This article was submitted to Frontiers
in Cancer Endocrinology, a specialty of
Frontiers in Endocrinology.
Copyright © 2012 Chinn, Darr, Peters
and Prince. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Endocrinology | Cancer Endocrinology August 2012 | Volume 3 | Article 90 | 6
